Top Story
Healthcare Marketing: Succeeding as an “Underdog”
If you are a healthcare marketer, you are also (almost certainly) an underdog marketer. So what do you do to win? Bill Drummy provides some answers that are simple to understand, but maybe difficult to implement.
...Read more
Launch
Four Launch Mistakes — and How to Avoid Them
In the white heat of a major brand launch, pharma companies can become consumed by the day to day challenges and make mistakes. But some of the worst mistakes can be avoided with a little foresight, writes Ken Begasse.
...Read more
On the road to integration
Moving your multichannel program into the fast lane
On Demand
Join Peter Lammers and Liz Murray from Quintiles as they present insightful research findings regarding the state of the pharmaceutical industry and the use of multi-channel marketing strategies. Learn what other industries apply successfully and get different options for you to actually "make it happen" for your product.
 Learn More
Supply Chain
Re-sell vs Direct Models: US Branded Drug Distribution in the Future
The US pharmaceutical supply chain has been undergoing a drastic transition from the buy-and-hold model to the fee-for-service model in the last 10 years. Kathleen Iacocca and Yao Zhao provide insights on why direct models can be more sustainable than resell models in the long run and whether they can be implemented in the US.
...Read more
Breaking through the complexity
Improving oncology treatment and access in the UK
On Demand
Join Dean Summerfield, Senior Vice President, Commercial and Consulting from Quintiles and Dr Jason Lester, Consultant Clinical Oncologist at the Velindre Cancer Centre as they discuss improving innovative oncology treatment and access in the UK.
 Learn More
Patients
Toward Real-World Patient Centricity
Despite industry-wide ambitions of patient centricity, new innovation in pharma is still almost exclusively evaluated on safety and medical efficacy in the clinical trial setting. Mikkel Brok-Kristensen suggests pharma takes a look at the invisible costs and the needs beyond efficacy.
...Read more
Patient adherence in Germany - benefit vs. cost-containment
On Demand
Join Joanne Thiele, Market Access Project Manager from Quintiles Germany and Hans Holger Bleβ, Director of Health Services Research department at IGES Institut GmbH as they discuss the importance of patient adherence programs in Germany.
 Learn More
Emerging Pharma Leaders
Pharm Exec’s Emerging Pharma Leaders 2015
The 2015 Emerging Pharma Leaders have been selected by PharmExec’s editorial staff with support from its Editorial Advisory Board. This year’s group adds to a list of more than 200 alumni dating back to June 2008. We called that first cohort of leaders “the change generation” and frankly the description remains apt today. What is different is a greater diversity in leader backgrounds and the skills required to advance to the “c-suite”.
...Read more
Emerging Pharma Leaders — Slide Show
If you’re pressed for time and want just the names and faces, click here for a slide show of PharmExec’s 17 Emerging Pharma Leaders 2015.
...Read more
| 
